Digestive Diseases and Sciences

, Volume 52, Issue 12, pp 3329–3333

Infliximab Delays but Does Not Avoid the Need for Surgery in Treatment-Resistant Pediatric Crohn’ Disease

  • N. A. Afzal
  • A. Ozzard
  • S. Keady
  • M. Thomson
  • S. Murch
  • R. Heuschkel


The aim of this study was to review the impact of infliximab therapy on children with treatment-resistant Crohn’s disease. Treatment resistance was defined as clinically active disease despite > 4 months of immunosuppressive therapy. The outcome variables were time to first remission, duration of remission and the need for surgery. 24 children received 90 infusions of infliximab (16 boys; median 10.3y, range 1.0–14.4y); all had three infusions as an induction course. 17 (70.8%) achieved clinical remission, with 14/17 (82.3%) relapsing within 4 months of the third infusion. 6/7 in the non-responding group and 8/17 of the responders required surgery with an insignificant difference in the median time to surgery (p = 0.49). Four remain dependent on regular infliximab. Infliximab is well-tolerated and highly effective in achieving clinical remission in children with refractory Crohn’s disease but may only delay and not avoid the need for surgery. Failure to achieve clinical remission by the 3rd infusion significantly increases the risk of surgery.

Key words

infliximab child Crohn’s disease inflammatory bowel disease treatment resistance surgery 


Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.


  1. 1.
    Murch SH, Lamkin VA, Savage MO, Walker–Smith JA, MacDonald TT: Serum concentrations of tumour necrosis factor alpha in childhood chronic inflammatory bowel disease. Gut 32(8):913–917, 1991PubMedCrossRefGoogle Scholar
  2. 2.
    Breese EJ, Michie CA, Nicholls SW, et al.: Tumor necrosis factor alpha-producing cells in the intestinal mucosa of children with inflammatory bowel disease. Gastroenterology 106(6):1455–1466, 1994PubMedGoogle Scholar
  3. 3.
    Hyams JS: Use of infliximab in the treatment of Crohn’s disease in children and adolescents. J Pediatr Gastroenterol Nutr 33 (Suppl 1):S36–S39, 2001Google Scholar
  4. 4.
    Kugathasan S, Levy MB, Saeian K, et al.: Infliximab retreatment in adults and children with Crohn’s disease: risk factors for the development of delayed severe systemic reaction. Am J Gastroenterol 97(6):1408–1414, 2002PubMedCrossRefGoogle Scholar
  5. 5.
    Kugathasan S: Prolonged duration of response to infliximab in early pediatric Crohn’s disease. J Pediatr Gastroenterol Nutr 33 (Suppl 1):S40–S43, 2001Google Scholar
  6. 6.
    Harvey RF, Bradshaw MJ: Measuring Crohn’s disease activity. Lancet 1(8178):1134–1135, 1980Google Scholar
  7. 7.
    Harvey RF, Bradshaw JM: A simple index of Crohn’s-disease activity. Lancet 1(8167):514, 1980Google Scholar
  8. 8.
    Eddy AA, Giachelli CM: Renal expression of genes that promote interstitial inflammation and fibrosis in rats with protein-overload proteinuria. Kidney Int 47(6):1546–1557, 1995PubMedCrossRefGoogle Scholar
  9. 9.
    Arnott ID, McDonald D, Williams A, Ghosh S: Clinical use of infliximab in Crohn’s disease: the Edinburgh experience. Aliment Pharmacol Ther 15(10):1639–1646, 2001PubMedCrossRefGoogle Scholar
  10. 10.
    Gasche C, Scholmerich J, Brynskov J, et al.: A simple classification of Crohn’s disease: report of the Working Party for the World Congresses of Gastroenterology, Vienna 1998. Inflamm Bowel Dis6(1):8–15, 2000Google Scholar
  11. 11.
    Ramakrishna J, Langhans N, Calenda K, Grand RJ, Verhave M: Combined use of cyclosporine and azathioprine or 6-mercaptopurine in pediatric inflammatory bowel disease. J Pediatr Gastroenterol Nutr 22(3):296–302, 1996PubMedCrossRefGoogle Scholar
  12. 12.
    Bousvaros, A: Oral tacrolimus treatment of fulminant colitis in children: long term follow-up. J Pediatr Gastroenterol Nutr 27(4):463, 1998 (abstract)Google Scholar
  13. 13.
    Cohen RD, Stein R, Hanauer SB: Intravenous cyclosporin in ulcerative colitis: a five-year experience. Am J Gastroenterol 94(6):1587–1592, 1999PubMedCrossRefGoogle Scholar
  14. 14.
    Sandborn WJ: Preventing antibodies to infliximab in patients with Crohn’s disease: Optimize not immunize. Gastroenterology 124(4):1140–1145, 2003PubMedGoogle Scholar
  15. 15.
    Hanauer SB, Feagan BG, Lichtenstein GR, et al.: Maintenance infliximab for Crohn’s disease: the ACCENT I randomised trial. Lancet 359(9317):1541–1549, 2002Google Scholar
  16. 16.
    Farrell RJ, Alsahli M, Jeen YT, Falchuk KR, Peppercorn MA, Michetti P: Intravenous hydrocortisone premedication reduces antibodies to infliximab in Crohn’s disease: a randomized controlled trial. Gastroenterology 124(4):917–924, 2003PubMedCrossRefGoogle Scholar
  17. 17.
    Rutgeerts P, D’Haens G, Targan S, et al.: Efficacy and safety of retreatment with anti–tumor necrosis factor antibody (infliximab) to maintain remission in Crohn’s disease. Gastroenterology 117(4):761–769, 1999PubMedCrossRefGoogle Scholar
  18. 18.
    Lionetti P, Bronzini F, Salvestrini C, et al.: Response to infliximab is related to disease duration in paediatric Crohn’s disease. Aliment Pharmacol Ther 18(4):425–431, 2003Google Scholar

Copyright information

© Springer Science + Business Media, LLC 2007

Authors and Affiliations

  • N. A. Afzal
    • 1
  • A. Ozzard
    • 2
  • S. Keady
    • 3
  • M. Thomson
    • 4
  • S. Murch
    • 2
  • R. Heuschkel
    • 2
    • 5
  1. 1.Department of PaediatricsSouthampton University Hospital NHS TrustSouthampton
  2. 2.Centre for Paediatric GastroenterologyLondonUK.
  3. 3.Department of PharmacyRoyal Free HospitalLondonUK.
  4. 4.Department of Paediatric GastroenterologySheffield Children’s HospitalSheffieldUK.
  5. 5.Centre for Pediatric GastroenterologyRoyal Free HospitalHampsteadUK

Personalised recommendations